The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm efficacy and safety study in subjects newly diagnosed with AL amyloidosis. Subjects will remain on-study until study completion, which will occur when all primary endpoint events (all-cause mortality or cardiac hospitalizations) have been reached.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: NEOD001
  • other: Placebo

Eligibility


Key Inclusion Criteria:

   1. Age ≥ 18 years

   2. Newly diagnosed, AL amyloidosis treatment naïve

   3. Bone marrow consistent with plasma cell dyscrasia

   4. Confirmed diagnosis of AL amyloidosis

   5. Cardiac involvement

   6. Planned first-line chemotherapy contains a proteasome-inhibiting agent administered
   weekly

   7. Adequate bone marrow reserve, hepatic and renal function

Key Exclusion Criteria:

   1. Non-AL amyloidosis

   2. Meets diagnostic criteria for symptomatic multiple myeloma

   3. Subject is eligible for and plans to undergo ASCT

   4. History of Grade ≥ 3 infusion-associated AEs or hypersensitivity to another monoclonal
   antibody, or known hypersensitivity to diphenhydramine or acetaminophen

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Explore Related Trials

All Stanford Trials

Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation,  mobile application development, and pharmaceutical trials.  

Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.